Health Catalyst (HCAT) Competitors

Health Catalyst (NASDAQ:HCAT) and Endava (NYSE:DAVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.

Do analysts recommend HCAT or DAVA?

Health Catalyst currently has a consensus price target of $8.00, indicating a potential upside of 113.05%. Endava has a consensus price target of $29.71, indicating a potential upside of 98.60%. Given Health Catalyst's stronger consensus rating and higher probable upside, equities research analysts plainly believe Health Catalyst is more favorable than Endava.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Endava	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.36

Does the media prefer HCAT or DAVA?

In the previous week, Endava had 26 more articles in the media than Health Catalyst. MarketBeat recorded 29 mentions for Endava and 3 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.46 beat Endava's score of 0.05 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Endava	6 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has preferable earnings and valuation, HCAT or DAVA?

Endava has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Endava, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.27M	0.84	-$118.15M	-$1.15	-3.27
Endava	$759.42M	1.16	$21.56M	$0.38	39.37

Is HCAT or DAVA more profitable?

Endava has a net margin of 0.74% compared to Health Catalyst's net margin of -26.20%. Endava's return on equity of 0.89% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-26.20%	-7.51%	-3.72%
Endava	0.74%	0.89%	0.61%

Which has more risk & volatility, HCAT or DAVA?

Health Catalyst has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Endava has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of HCAT or DAVA?

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 62.2% of Endava shares are owned by institutional investors. 2.5% of Health Catalyst shares are owned by company insiders. Comparatively, 18.8% of Endava shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor HCAT or DAVA?

Endava received 50 more outperform votes than Health Catalyst when rated by MarketBeat users. However, 67.21% of users gave Health Catalyst an outperform vote while only 58.22% of users gave Endava an outperform vote.

Company	Underperform	Outperform
Health Catalyst	Outperform Votes 166 67.21%	Underperform Votes 81 32.79%
Endava	Outperform Votes 216 58.22%	Underperform Votes 155 41.78%

Summary

Endava beats Health Catalyst on 11 of the 18 factors compared between the two stocks.